Compare PFBC & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFBC | BBOT |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | PFBC | BBOT |
|---|---|---|
| Price | $90.91 | $10.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $102.67 | $23.71 |
| AVG Volume (30 Days) | 76.9K | ★ 269.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.94 | N/A |
| Revenue Next Year | $8.31 | N/A |
| P/E Ratio | $8.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $73.08 | $8.70 |
| 52 Week High | $103.05 | $14.87 |
| Indicator | PFBC | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 41.97 |
| Support Level | $88.78 | $9.15 |
| Resistance Level | $93.52 | $12.65 |
| Average True Range (ATR) | 2.24 | 0.75 |
| MACD | 0.40 | -0.06 |
| Stochastic Oscillator | 90.72 | 21.87 |
Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking which includes Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals. The bank generates a majority of its revenue from Southern and Northern California and Flushing.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.